Cardio Diagnostics (CDIO) vs ImmuCell (ICCC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
ImmuCell is the larger company by market cap ($99.3 million vs $4.7 million), about 21.0 times the size. ImmuCell converts more of its revenue into profit, with a net margin of -3.8% versus -43832.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CDIO | ICCC |
|---|---|---|
| Share price | $1.60 | $10.92 |
| Market cap | $4.74M | $99.28M |
| 1-day change | -3.03% | -2.41% |
| YTD return | — | +77.56% |
| 1-year return | — | +133.33% |
| 5-year return | — | +18.70% |
| P/E ratio (TTM) | — | 57.47 |
| EPS (TTM) | $-2.52 | $0.19 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $14.82K | $27.64M |
| Revenue growth (YoY) | -57.51% | +4.34% |
| Net income (latest FY) | $-6.50M | $-1.04M |
| Gross margin | — | 41.40% |
| Operating margin | -43737.46% | 5.97% |
| Net margin | -43832.49% | -3.76% |
| 52-week high | $7.91 | $12.10 |
| 52-week low | $0.97 | $4.67 |
| Distance from 52-week high | -79.77% | -9.75% |
| Average volume | 26.91K | 13.44K |
| Shares outstanding | 2.96M | 9.09M |
| Employees | 15 | 73 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ImmuCell is about 21.0 times larger than Cardio Diagnostics by market value ($99.28M vs $4.74M).
- ImmuCell is more profitable, keeping -3.8 cents of every revenue dollar as net income versus -43832.5 cents for Cardio Diagnostics.
- ImmuCell grew revenue faster in its latest fiscal year (+4.34% vs -57.51%).
About Cardio Diagnostics
CDIO stock →Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 15 employees
About ImmuCell
ICCC stock →ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 73 employees
CDIO vs ICCC FAQ
Which is bigger, Cardio Diagnostics or ImmuCell?
ImmuCell (ICCC) is larger, with a market capitalization of $99.28M compared with $4.74M for Cardio Diagnostics (CDIO).
Are Cardio Diagnostics and ImmuCell in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.